ProtoKinetix, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>ProtoKinetix, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

ProtoKinetix, Inc. (PKTX) filed a Annual Report (10-K) with the SEC on March 20, 2024. ProtoKinetix, Inc. filed its 2023 10-K report on March 20, 2024. The company's fiscal year ends on December 31st. ProtoKinetix, Inc. is incorporated in Nevada. The company's principal business address is 109 W. Main St., Dalton, OH 44618. The SIC code for ProtoKinetix, Inc. is 2834 (Pharmaceutical Preparations).

Why It Matters

For investors and stakeholders tracking ProtoKinetix, Inc., this filing contains several important signals. The filing provides a comprehensive overview of the company's financial health and strategic direction for the past fiscal year. Investors and stakeholders can use this report to assess the company's performance, identify potential risks, and make informed investment decisions.

Risk Assessment

Risk Level: low — ProtoKinetix, Inc. shows low risk based on this filing. The filing is a standard 10-K annual report, which typically contains routine financial and operational information without immediate market-moving news.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand ProtoKinetix, Inc.'s current financial position and future outlook.

Key Players & Entities

• ProtoKinetix, Inc. (company) — Filer
• 2023 (date) — Fiscal Year
• March 20, 2024 (date) — Filing Date
• December 31 (date) — Fiscal Year End
• Nevada (location) — State of Incorporation
• 109 W. Main St., Dalton, OH 44618 (address) — Business Address
• 2834 (industry) — SIC Code
• Pharmaceutical Preparations (industry) — SIC Code Description

FAQ

Industry Context

ProtoKinetix, Inc. operates within the Pharmaceutical Preparations industry, indicated by its SIC code 2834.

Regulatory Implications

The company is subject to SEC regulations for public filings, including the annual 10-K report.

What Investors Should Do

1. Analyze the financial statements for revenue, net income, and other key metrics.
2. Review the risk factors section for potential challenges and uncertainties.
3. Examine management's discussion and analysis for insights into business strategy and outlook.

Key Dates

• 2024-03-20: 10-K Filing — Filing of the annual report for the fiscal year ended December 31, 2023.

Year-Over-Year Comparison

This is the initial filing analyzed for the current period.

Key Financial Figures

• $0.0243 — ing price of our common stock which was $0.0243 as of June 30, 2023, the last business
• $448,873 — al research and development expenses of $448,873. For the year ended December 31, 2023,
• $112,444 — al research and development expenses of $112,444. In order to reach the Company's goals
• $415,479 — t our recurring losses from operations ($415,479 and $1,907,309 for the years ended Dece
• $1,907,309 — ng losses from operations ($415,479 and $1,907,309 for the years ended December 31, 2023 a
• $375,989 — ) and negative net operating cash flow ($375,989 and $804,669 for the years ended Decemb
• $804,669 — e net operating cash flow ($375,989 and $804,669 for the years ended December 31, 2023 a

Filing Documents

• pktx_10k.htm (10-K) — 862KB
• ex4x6.htm (EX-4.6) — 21KB
• ex31x1.htm (EX-31.1) — 15KB
• ex31x2.htm (EX-31.2) — 15KB
• ex32x1.htm (EX-31.2) — 6KB
• davidson.jpg (GRAPHIC) — 13KB
• image_003.jpg (GRAPHIC) — 13KB
• 0001079973-24-000403.txt (&nbsp;) — 4002KB
• pktx-20231231.xsd (EX-101.SCH) — 32KB
• pktx-20231231_cal.xml (EX-101.CAL) — 28KB
• pktx-20231231_def.xml (EX-101.DEF) — 120KB
• pktx-20231231_lab.xml (EX-101.LAB) — 264KB
• pktx-20231231_pre.xml (EX-101.PRE) — 229KB
• pktx_10k_htm.xml (XML) — 482KB

Business

Business 3 Item 1A

Risk Factors

Risk Factors 4 Item 1B Unresolved Staff Comments 9 Item 1C Cybersecurity 9 Item 2

Properties

Properties 9 Item 3

Legal Proceedings

Legal Proceedings 9 Item 4 Mine Safety Disclosures 9 Part II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 10 Item 6 [Reserved] 12 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 15 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 15 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 16 Item 9A

Controls and Procedures

Controls and Procedures 16 Item 9B Other Information 17 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 17 Part III Item 10 Directors, Executive Officers and Corporate Governance 18 Item 11

Executive Compensation

Executive Compensation 20 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 23 Item 13 Certain Relationships and Related Transactions, and Director Independence 24 Item 14 Principal Accountant Fees and Services 24 Part IV Item 15 Exhibits and Financial Statement Schedules 25 Item 16 Form 10-K Summary 26

Signatures

Signatures 27 2 PART I ITEM1. BUSINESS ProtoKinetix, Incorporated ("ProtoKinetix," "we," "us," "our," or the "Company") is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs . The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP to market. ProtoKinetix was incorporated as RJV Network, Inc. under the laws of the State of Nevada on December 23, 1999 for the primary purpose of developing an internet-based listing site that would provide detailed commercial real estate property listings and related data. In July 2003, the Company entered into an assignment of license agreement with BioKinetix Research, Incorporated for the assignment of rights relating to proprietary technologies of BioKinetix Research, Incorporated for the creation and commercialization of "superantibodies." On July 8, 2003, the Company changed its name to "ProtoKinetix, Incorporated." The Company's executive (or corporate) offices are located at 109 W Main St, Dalton, Ohio 44618. Our telephone number is (330) 445-4971 and our website is www.protokinetix.com. Cautionary Note Regarding Forward-Looking Statements The information discussed in this Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as well as some statements in press releases and some oral statements of the Company's officers during presentations about the Company include "forward looking of the Securities Exchange Act of 1934 (the "Exchange Act"). All statements, ot

View Full Filing

View this 10-K filing on SEC EDGAR